Regulatory 2025-03-18 | Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 PDF Report Presentation Webcast
Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-02-04 | Ascelia Pharma Secures Financing of up to SEK 35 Million PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Presentation Webcast
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Report Presentation Webcast
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® PDF Report Presentation Webcast
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study PDF Report Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma has carried out a directed new share issue raising SEK 200 million PDF Report Presentation Webcast
Regulatory 2021-03-17 | Ascelia Pharma intends to carry out a directed new share issue PDF Report Presentation Webcast
Regulatory 2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral PDF Report Presentation Webcast
Regulatory 2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent PDF Report Presentation Webcast
Regulatory 2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually PDF Report Presentation Webcast
Regulatory 2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact PDF Report Presentation Webcast
Regulatory 2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral PDF Report Presentation Webcast
Regulatory 2020-02-19 | First patient enrolled in pivotal Phase III clinical study SPARKLE with lead candidate Mangoral PDF Report Presentation Webcast
